10-Q: Precision BioSciences Reports Q3 Results, Advances In Vivo Gene Editing Programs

Precision BioSciences reports a net loss of $16.4 million for Q3 2024, while highlighting progress in its in vivo gene editing programs and strategic collaborations.

Summary

• Precision BioSciences reported a net loss of $16.4 million for the third quarter of 2024, compared to a net loss of $8.1 million in the same period of 2023.
• The company's revenue decreased to $0.6 million in Q3 2024 from $13.1 million in Q3 2023, primarily due to reduced revenue from the Novartis and Prevail agreements.
• Research and development expenses were $13.1 million for Q3 2024, down from $15.9 million in Q3 2023, with a shift in focus towards in vivo programs.
• The company highlighted the receipt of a clinical trial application approval in Moldova for its PBGENE-HBV program and progress in its PBGENE-3243 program for mitochondrial disease.
• Precision Biosciences also noted the ongoing Phase 1/2 trial by iECURE for OTC deficiency using their ARCUS technology and the receipt of Fast Track designation from the FDA for ECUR-506.
• The company's cash and cash equivalents totaled $98.8 million as of September 30, 2024, with an additional $22.6 million in restricted cash.
• Precision Biosciences believes its current cash resources will fund operations into the second half of 2026, sufficient to achieve first-in-human Phase 1 clinical data for two wholly-owned in vivo gene editing programs.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is progress in clinical programs and a sufficient cash runway, the increased net loss and decreased revenue are concerning. The company is making progress in its pipeline, but faces significant risks and challenges.

Positives

• The company received a clinical trial application approval in Moldova for its PBGENE-HBV program, indicating progress in its in vivo gene editing pipeline.
• iECURE, a partner, received Fast Track designation from the FDA for ECUR-506, highlighting the potential of their ARCUS-mediated gene insertion approach.
• The company believes its current cash resources will fund operations into the second half of 2026, providing a runway to achieve key clinical milestones.
• Preclinical data for PBGENE-HBV and PBGENE-3243 programs show promising results, supporting their advancement to clinical trials.
• The company demonstrated high-efficiency gene insertion using ARCUS in preclinical work.

Negatives

• The company reported a net loss of $16.4 million for Q3 2024, an increase from the $8.1 million loss in Q3 2023.
• Revenue decreased significantly to $0.6 million in Q3 2024, down from $13.1 million in Q3 2023, due to reduced collaboration revenue.
• The termination of the Prevail agreement resulted in a loss of revenue and deferred revenue.
• The company is still in the early stages of product development, with no products yet approved for commercial sale.

Risks

• The company has a limited operating history, making it difficult to evaluate its future prospects.
• The ARCUS technology is novel, making it difficult to predict the time, cost, and success of product development.
• The company is heavily dependent on the successful development of ARCUS and its product candidates.
• Adverse public perception of genome editing could negatively impact the company's progress.
• The company faces significant competition in the rapidly evolving genome editing field.
• Clinical trials are expensive, time-consuming, and involve uncertain outcomes.
• Manufacturing of product candidates may be complex and difficult, leading to potential delays.
• The company may need to raise additional capital, which could dilute existing stockholders or restrict operations.
• The company is subject to various regulatory risks and may face delays or termination of development programs.
• The company's product candidates may not achieve market acceptance even if approved.

Future Outlook

Precision BioSciences believes its current cash resources will fund operations into the second half of 2026, sufficient to achieve first-in-human Phase 1 clinical data for two wholly-owned in vivo gene editing programs. The company expects to submit an IND and/or CTA application in 2025 with respect to PBGENE-3243.

Management Comments

• The company is solely focused on leveraging its proprietary ARCUS genome editing platform to advance in vivo gene editing programs.
• The company is continuing to evaluate returned programs to determine the appropriate next steps with each of them.
• The company believes specificity is of particular importance for developing a safe gene editing approach to eliminating HBV.
• Preclinical safety data supports the advancement of PBGENE-HBV to clinical trials as a potentially curative treatment for chronic hepatitis B.

Industry Context

The announcement reflects the ongoing trend in the biopharmaceutical industry towards gene editing and in vivo therapies. The company's focus on complex edits and gene insertion aligns with the growing interest in more sophisticated gene editing approaches beyond simple knockouts. The collaboration with iECURE and the Fast Track designation for ECUR-506 also highlight the increasing regulatory support for gene therapy development.

Comparison to Industry Standards

• The reported net loss is consistent with the financial profile of clinical-stage biotechnology companies that are heavily investing in research and development.
• The decrease in revenue is typical for companies transitioning from collaboration-based revenue to focusing on their own pipeline.
• The cash runway into the second half of 2026 is a positive sign, as it provides a longer period for the company to achieve key clinical milestones.
• The progress in the PBGENE-HBV and PBGENE-3243 programs is comparable to other companies in the gene editing space, with a focus on in vivo delivery and complex edits.
• The collaboration with iECURE and the Fast Track designation for ECUR-506 are positive indicators of the potential of the ARCUS technology, similar to other companies that have received regulatory support for their gene therapy programs.
• The company's focus on specific diseases with high unmet needs, such as chronic hepatitis B and mitochondrial disease, is a common strategy in the biopharmaceutical industry.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased revenue, but encouraged by the progress in clinical programs.
• Employees may be affected by the strategic shift and potential changes in resource allocation.
• Customers and partners may be interested in the progress of the company's in vivo gene editing programs and collaborations.
• Creditors may be reassured by the company's cash runway and the new loan agreement.

Next Steps

• The company will continue to advance its PBGENE-HBV program towards clinical trials.
• The company expects to submit an IND and/or CTA application in 2025 with respect to PBGENE-3243.
• The company will continue to evaluate returned programs to determine the appropriate next steps.
• The company will continue to evaluate the ARCUS platform with regards to safety, on-target editing, gene insertion, complex gene edits, and compatibility with viral and non-viral delivery.

Key Dates

Keywords

gene editing, in vivo, ARCUS, PBGENE-HBV, PBGENE-3243, clinical trials, biotechnology, pharmaceutical, mitochondrial disease, hepatitis B, regulatory approval, collaboration, licensing